208 related articles for article (PubMed ID: 21878358)
1. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP
Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358
[TBL] [Abstract][Full Text] [Related]
2. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
Palus K; Całka J; Jana B
Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.
Lara-Marquez ML; O'Dorisio MS; Karacay B
Ann N Y Acad Sci; 2000; 921():45-54. PubMed ID: 11193874
[TBL] [Abstract][Full Text] [Related]
5. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
Sun W; Hong J; Zang YC; Liu X; Zhang JZ
Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
[TBL] [Abstract][Full Text] [Related]
7. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.
Lara-Marquez M; O'Dorisio M; O'Dorisio T; Shah M; Karacay B
J Immunol; 2001 Feb; 166(4):2522-30. PubMed ID: 11160313
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.
Jimeno R; Leceta J; Martínez C; Gutiérrez-Cañas I; Carrión M; Pérez-García S; Garín M; Mellado M; Gomariz RP; Juarranz Y
J Mol Neurosci; 2014 Nov; 54(3):512-25. PubMed ID: 24805298
[TBL] [Abstract][Full Text] [Related]
9. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
Szilasi M; Buglyo A; Treszl A; Kiss L; Schally AV; Halmos G
Int J Oncol; 2011 Oct; 39(4):1019-24. PubMed ID: 21769421
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and its receptors in human ovarian cortical follicles.
Gabbay-Benziv R; Ao A; Fisch B; Zhang L; Oron G; Kessler-Icekson G; Ben-Haroush A; Krissi H; Abir R
PLoS One; 2012; 7(5):e37015. PubMed ID: 22623971
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M
Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881
[TBL] [Abstract][Full Text] [Related]
13. VPAC
Cunha-Reis D; Ribeiro JA; de Almeida RFM; Sebastião AM
Br J Pharmacol; 2017 Dec; 174(24):4725-4737. PubMed ID: 28945273
[TBL] [Abstract][Full Text] [Related]
14. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
15. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.
Voice JK; Grinninger C; Kong Y; Bangale Y; Paul S; Goetzl EJ
J Immunol; 2003 Jan; 170(1):308-14. PubMed ID: 12496414
[TBL] [Abstract][Full Text] [Related]
16. VPAC1 and VPAC2 receptor deficiencies negatively influence pregnancy outcome through distinct and overlapping modulations of immune, trophoblast and vascular functions.
Calo G; Hauk V; Vota D; Van C; Condro M; Gallino L; Ramhorst R; Waschek J; Pérez Leirós C
Biochim Biophys Acta Mol Basis Dis; 2023 Feb; 1869(2):166593. PubMed ID: 36328148
[TBL] [Abstract][Full Text] [Related]
17. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.
Jayawardena D; Guzman G; Gill RK; Alrefai WA; Onyuksel H; Dudeja PK
Am J Physiol Gastrointest Liver Physiol; 2017 Jul; 313(1):G16-G25. PubMed ID: 28385693
[TBL] [Abstract][Full Text] [Related]
18. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
19. VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.
Shi H; Carion TW; Jiang Y; Steinle JJ; Berger EA
Prostaglandins Other Lipid Mediat; 2016 Mar; 123():28-32. PubMed ID: 27026343
[TBL] [Abstract][Full Text] [Related]
20. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
